We are live on !
Find out more
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
Turnover
18.46%
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter Est. Return
-11.1%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$55.3M
AUM Growth
-$12.2M
(-18%)
Cap. Flow
-$3.77M
Cap. Flow % of AUM
Cap. Flow %
-6.81%
Top 10 Holdings %
Top 10 Hldgs %
62.56%
Holding
65
New
2
Increased
18
Reduced
1
Closed
10
Avg Time Held
Equity + Options
2.1
years
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
1.3
years
Avg Time Held Equity only
2.1
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortress Biotech
FBIO
|
+$595K |
| 2 |
Amarin Corp
AMRN
|
+$297K |
| 3 |
United Therapeutics
UTHR
|
+$282K |
| 4 |
Alkermes
ALKS
|
+$253K |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.5K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$868K |
| 2 |
Sarepta Therapeutics
SRPT
|
+$813K |
| 3 |
bluebird bio
BLUE
|
+$743K |
| 4 |
Insmed
INSM
|
+$690K |
| 5 |
Pacira BioSciences
PCRX
|
+$489K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.66% |
| 2 | Miscellaneous | 43.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Amarin Corp
AMRN
$491M
| $510K | 0.92% |
1,682
+850
| +102% | +$297K |
2019 Q1
2 quarters
|
|
27
DELISTED
Blueprint Medicines
BPMC
| $498K | 0.9% |
6,780
| – | – |
2019 Q1
2 quarters
|
|
28
DELISTED
Audentes Therapeutics, Inc
BOLD
| $487K | 0.88% |
17,339
| – | – |
2019 Q1
2 quarters
|
|
29
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $475K | 0.86% |
20,844
| – | – |
2019 Q1
2 quarters
|
|
|
GBT
30
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $460K | 0.83% |
9,479
| – | – |
2019 Q1
2 quarters
|
|
31
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $453K | 0.82% |
10,852
| – | – |
2019 Q1
2 quarters
|
|
|
ARNA
32
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $447K | 0.81% |
9,770
| – | – |
2019 Q1
2 quarters
|
|
33
Acadia Pharmaceuticals
ACAD
$3.14B
| $432K | 0.78% |
12,005
+24
| +0.2% | +$728 |
2017 Q3
8 quarters
|
|
|
GWPH
34
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $423K | 0.76% |
3,674
| – | – |
2019 Q1
2 quarters
|
|
|
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
| $389K | 0.7% |
9,725
| – | – |
2019 Q1
2 quarters
|
|
36
MacroGenics
MGNX
$146M
| $384K | 0.69% |
30,075
| – | – |
2019 Q1
2 quarters
|
|
37
Intellia Therapeutics
NTLA
$1.48B
| $380K | 0.69% |
28,490
| – | – |
2019 Q1
2 quarters
|
|
38
Bio-Techne
TECH
$11.4B
| $303K | 0.55% |
6,204
| – | – |
2016 Q4
11 quarters
|
|
39
IQVIA
IQV
$44.7B
| $297K | 0.54% |
1,985
| – | – |
2016 Q2
13 quarters
|
|
40
Amgen
AMGN
$253B
| $294K | 0.53% |
1,518
+121
| +9% | +$23.2K |
2014 Q4
19 quarters
|
|
41
Neurocrine Biosciences
NBIX
$17.1B
| $282K | 0.51% |
3,127
+115
| +4% | +$10.7K |
2016 Q3
12 quarters
|
|
42
DELISTED
Checkpoint Therapeutics
CKPT
| $281K | 0.51% |
11,276
| – | – |
2017 Q2
9 quarters
|
|
43
Charles River Laboratories
CRL
$16.3B
| $280K | 0.51% |
2,112
| – | – |
2016 Q4
11 quarters
|
|
|
44
United Therapeutics
UTHR
$25.3B
| $279K | 0.5% |
+3,498
| New | +$282K |
2019 Q3
0 quarters
|
|
45
Grifois
GRFS
$5.99B
| $264K | 0.48% |
13,196
| – | – |
2016 Q2
13 quarters
|
|
46
Biogen
BIIB
$37B
| $261K | 0.47% |
1,123
| – | – |
2019 Q2
1 quarter
|
|
|
ICPT
47
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $261K | 0.47% |
3,926
-1,946
| -33% | -$131K |
2016 Q3
12 quarters
|
|
48
Gilead Sciences
GILD
$208B
| $259K | 0.47% |
4,082
| – | – |
2016 Q4
11 quarters
|
|
49
Ligand Pharmaceuticals
LGND
$6.33B
| $242K | 0.44% |
3,892
+508
| +15% | +$31.9K |
2019 Q1
2 quarters
|
|
50
Nektar Therapeutics
NKTR
$1.27B
| $235K | 0.42% |
862
+28
| +3% | +$10.3K |
2014 Q4
19 quarters
|
|
Similar funds
FCM
Opus Point Partners Management's Q3 2019 Portfolio in Review
As of Q3 2019, Opus Point Partners Management held 65 positions worth $55.3M, down 18% from $67.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Opus Point Partners Management withdrew a net $3.77M in Q3 2019, closing 10 positions and reducing 1 holding. Its most notable exit was Immunomedics Inc, an estimated $868K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 59% a quarter earlier, followed by Miscellaneous.
Against the trend, Opus Point Partners Management opened a new position in United Therapeutics worth $279K.
- Opus Point Partners Management's largest Q3 2019 buy was United Therapeutics: 3,498 shares worth $279K.
- Opus Point Partners Management added most to Fortress Biotech in Q3 2019, an estimated $595K increase.
- Opus Point Partners Management's biggest Q3 2019 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $131K.
- Opus Point Partners Management fully exited Immunomedics Inc in Q3 2019, selling an estimated $868K.
- Opus Point Partners Management's ten largest holdings make up 63% of its $55.3M portfolio in Q3 2019.
- Opus Point Partners Management opened 2 new positions and closed 10 in Q3 2019.
- Opus Point Partners Management's portfolio value fell 18% quarter-over-quarter to $55.3M.
Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.